HAIKOU CITY, China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. ("China Pharma") (NYSE Amex: CPHI), which develops, manufactures, and markets specialty pharmaceutical products in China, today announced that the Company has successfully completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic.
Cephalosporin continues to be the most widely prescribed class of antibiotics in China. According to the SFDA, approximately 50% of antibiotic sales are derived from cephalosporin. Sales of cephalosporin antibiotics were estimated to be over $6 billion in 2009, and are projected to be $7.5 billion in 2010, $11 billion in 2012, and $17.4 billion in 2015. Due to broad usage of antibiotics, including cephalosporin, drug resistance has become a significant issue in China. The Company believes its new combination antibiotic possesses substantial competitive advantages in this environment, and believes the market opportunity for this drug can reach $50 million within three years of product launch. The SFDA has designated the Company's combination antibiotic as a Class 1 drug, which carries five-year exclusivity when approved.
The Company's anti-drug-resistance antibiotic, which combines a 3rd generation cephalosporin and a beta-lactamase inhibitor, is expected to be indicated for a wide variety of infections throughout the body, including: upper and lower respiratory tract infections (especially for pneumonia and bronchitis), ear and nose infections, bacterial Septicemia, meningitis, skin and skin structure infections, bone and joint infections, abdominal infections (peritonitis, cholecystitis, etc.), upper and lower urinary tract infections, gonorrhea, and genital infections.
Greater prevalence of drug-resistant extended-spectrum beta-lactamase (ESBL) producing bacteria, such as the enterobacteriaceae family, has prom
|SOURCE China Pharma Holdings, Inc.|
Copyright©2010 PR Newswire.
All rights reserved